LeapRate's Daily Forex Industry Newsletter
Join now to receive first access to our EXCLUSIVE reports and updates.
Screenshot of a breaking news alert e-mail from Q2 2017
Australian drug development company Noxopharm (ASX:NOX) has been successfully listed on Australia Securities Exchange (ASX) and will begin trading on Tuesday, August 9, 2016 at 11 am (AEST), after the Initial Public Offer raised the target figure of 6 million Australian dollars.
The offer of 30 million shares at a price of $0.20 a share, which was heavily oversubscribed, was led by Asia Pacific Prudential Securities (APP Securities).
The capital will be used to begin clinical trials later this year on its frontline drug candidate, NOX66, which is a drug technology that aims to provide a means of overcoming the resistance of cancer cells to standard-of-care chemotherapies.